PetMed Express (Nasdaq: PETS ) is expected to report Q3 earnings around Jan. 14. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict PetMed Express's revenues will wane -4.2% and EPS will wane -10.5%.
The average estimate for revenue is $48.4 million. On the bottom line, the average EPS estimate is $0.17.
Last quarter, PetMed Express booked revenue of $58.1 million. GAAP reported sales were 0.1% lower than the prior-year quarter's $58.2 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at $0.20. GAAP EPS of $0.20 for Q2 were 5.3% higher than the prior-year quarter's $0.19 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 33.3%, 90 basis points worse than the prior-year quarter. Operating margin was 10.9%, 50 basis points better than the prior-year quarter. Net margin was 6.9%, 20 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $229.8 million. The average EPS estimate is $0.74.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 858 members out of 886 rating the stock outperform, and 28 members rating it underperform. Among 236 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 229 give PetMed Express a green thumbs-up, and seven give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on PetMed Express is hold, with an average price target of $9.50.
Can your portfolio provide you with enough income to last through retirement? You'll need more than PetMed Express. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
- Add PetMed Express to My Watchlist.